TOP > News Release > list in 2008
- 2008.12.19
- Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japanfs Daiichi Sankyo
Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board
- 2008.12.19
- Announcement regarding ActHib®(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b) launch
- 2008.12.19
- Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
- 2008.12.11
- Daiichi Sankyo Submits Application for Approval of CS-866AZ Antihypertensive Combination Drug in Japan
- 2008.12.08
- NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
- 2008.11.26
- DAIICHI SANKYO sets up subsidiary in Ireland
Critical step in European expansion
- 2008.11.17
- DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.11.13
- Daiichi Sankyo's Research Foundation Establishes First Annual Clinical Pharmacology Research Award
- 2008.11.13
- DAIICHI SANKYO EUROPE GmbH announce SEVIKAR® a new fixed dose combination treatment for essential hypertension
- 2008.11.11
- ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
Product development agreement focused on ARQ 197, c-Met inhibitor,with discovery collaboration directed toward novel kinase inhibitors;
- 2008.11.10
- Announcement regarding ActHib(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)launch date
- 2008.10.31
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.10.20
- Daiichi Sankyo and Ranbaxy Move Forward Toward
The Completion of the Landmark Deal
- 2008.10.17
- Daiichi Sankyo and Lilly Respond to Speculation
On Status of Prasugrel New Drug Application
- 2008.09.30
- Announcement regarding ActHib(R)(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)
- 2008.09.02
- Daiichi Sankyo Announces Clinical Study Data for
Oral Factor Xa Inhibitor DU-176b
- 2008.08.25
- Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
